Viloxazine Hydrochloride Drug Due Diligence Report 2026

This Viloxazine Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Viloxazine Hydrochloride can convert its Small molecule drug profile and NET biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Viloxazine Hydrochloride (query alias: Viloxazine Hydrochloride)
Modality / target	Small molecule drug; NET; NET inhibitors
Highest global status	Approved
Originator	Supernus Pharmaceuticals, Inc.
Active developers	Knight Therapeutics, Inc., Supernus Pharmaceuticals, Inc.

The MCP disease footprint includes Nervous System Diseases, Attention Deficit Disorder With Hyperactivity. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06185985	Phase 4	Completed	161	Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.
NCT06259331	Phase 4	Completed	15	AUCtau,Milk
NCT07678827	Phase 3	Not yet recruiting	156	Change From Baseline to Week 8 in K-ARS-5 (Korean ADHD Rating Scale, 5th Edition) Total Score

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms

Phase 4; n=161; evaluation: Positive. Reported fields: AISRS(total score) = -17.3 point ( 11.34)

A Phase IV, Open-Label, Decentralized Clinical Trial to Evaluate the Efficacy and Safety of Qelbree® in Adults With Attention-Deficit/Hyperactivity Disorder and Mood Symptoms

Phase 4; n=161; evaluation: not stated. Reported fields: Raw score; Baseline(Mean) = 37.5 score on a scale (Standard Deviation, 6.53); -; -

Effect of viloxazine and trazodone in obstructive sleep apnoea: a randomised, placebo-controlled, cross-over study

Phase 2; n=24; evaluation: Positive. Reported fields: TFST = 22.3 min ( -1.4 to 46.0)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Viloxazine Hydrochloride addresses Nervous System Diseases, Attention Deficit Disorder With Hyperactivity. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-05-08	Lotus Enters Into Exclusive License Agreement With Supernus Pharmaceuticals for Qelbree® (viloxazine) in Major APAC Countries	Approved	Financial terms not disclosed
2024-05-07	Acino signs an exclusive license agreement with Supernus in Latin America	Approved	Financial terms not disclosed
2006-06-01	Supernus Pharmaceuticals entered into a purchase and sale agreement with Rune Healthcare Limited, or Rune	Not disclosed	US$0.0M upfront

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO